Cue biopharma reports second quarter 2023 financial results and recent business highlights

Boston, aug. 09, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific t cells directly within the patient's body, provided a business and financial update for the second quarter 2023.
CUE Ratings Summary
CUE Quant Ranking